688765 禾元生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-2.186-8.976-22.711-22.984-32.075
总资产报酬率 ROA (%)-1.662-6.592-14.957-18.109-26.042
投入资产回报率 ROIC (%)-1.932-7.663-18.269-21.466-31.449

边际利润分析
销售毛利率 (%)48.82937.09163.48954.26963.587
营业利润率 (%)-351.871-329.301-600.283-770.655-1,060.405
息税前利润/营业总收入 (%)-339.482-316.661-588.876-790.906-1,181.568
净利润/营业总收入 (%)-343.417-328.109-600.283-770.533-1,071.488

收益指标分析
经营活动净收益/利润总额(%)147.000113.440111.598107.861102.413
价值变动净收益/利润总额(%)-12.843-0.5780.0000.0000.000
营业外收支净额/利润总额(%)-2.462-0.3630.000-0.0161.034

偿债能力分析
流动比率 (X)2.9994.7671.0202.3922.350
速动比率 (X)2.6134.5040.8052.0962.215
资产负债率 (%)26.14921.74043.36623.96418.810
带息债务/全部投入资本 (%)8.2208.10022.1039.3521.573
股东权益/带息债务 (%)1,072.7591,093.949328.494943.7786,233.151
股东权益/负债合计 (%)282.431359.988130.596317.298431.644
利息保障倍数 (X)-86.276-27.662-51.62238.82110.734

营运能力分析
应收账款周转天数 (天)4.5982.2192.4742.1662.415
存货周转天数 (天)3,479.2811,012.3561,676.400995.8801,893.558